Stockscreener 앱 받기
29.50
0.10%
-0.03
시간 외 거래:
29.52
0.02
+0.07%
전일 마감가:
$29.53
열려 있는:
$28.89
하루 거래량:
383.68K
Relative Volume:
5.04
시가총액:
$3.04B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.00%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$28.77
$30.26
1주일 범위
$25.06
$30.26
52주 변동 폭
$25.06
$30.26
Metsera Inc Stock (MTSR) Company Profile
MTSR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
29.50 | 3.04B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Metsera Inc 주식(MTSR)의 최신 뉴스
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares - The Manila Times
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to - EIN News
Metsera shares leap on strong IPO performance By Investing.com - Investing.com Nigeria
Metsera shares leap on strong IPO performance - MSN
Metsera IPO opens 42% higher - MSN
Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut - MSN
Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs - MSN
Finance Watch: Metsera, Maze Go Public, Bringing 2025 US IPO Total To Three - News & Insights
Metsera hits $2.7 bln valuation as shares surge 42% in Nasdaq debut - Reuters
Metsera (MTSR) Opens At $25.50, IPO Priced At $18 By Investing.com - Investing.com Australia
Metsera Inc (MTSR): GLP-1 Boom Comes to the IPO Market with Explosive Debut - Smartkarma
Metsera and Maze Therapeutics Secure $415M in IPOs, Signaling Strong Start for US Health Care Industry - Hoodline
Metsera (MTSR) Opens At $25.50, IPO Priced At $18 - Investing.com
Metsera sees stock rally 54% following $275M IPO - MSN
Weight-loss drug developer Metsera raises $275 million in US IPO - MSN
Metsera sees stock rally 54% following $275M IPO (MTSR:NASDAQ) - Seeking Alpha
Metsera IPO opens 42% higher By Investing.com - Investing.com Nigeria
Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut -January 31, 2025 at 01:02 pm EST - Marketscreener.com
Metsera Shares Rise Sharply in Nasdaq Debut -January 31, 2025 at 01:03 pm EST - Marketscreener.com
4 Firms Guide Pair Of Biotech IPOs Raising $415M Combined - Law360
Metsera and Maze IPOs look to bring $415M to Nasdaq - BioWorld Online
Obesity-drug maker Metsera posts largest gain as IPOs defy market swoon - MarketWatch
MTSR IPO NewsObesity biotech Metsera offers fewer shares, prices IPO above the range at $18 - Renaissance Capital
Busy day for biotech IPOs as Metsera, Maze go public with offerings totaling nearly $400M - Fierce Biotech
Two more biotechs, Metsera and Maze, cross IPO finish line - pharmaphorum
Metsera and Maze Therapeutics Boost US Health Care IPOs to Record LevelsNews and Statistics - IndexBox, Inc.
Metsera Prices of Initial Public Offering - citybiz
Metsera, Maze raise a combined $415M in IPO double-header - FirstWord Pharma
Metsera, Maze secure combined $415 million in IPOs - BioPharma Dive
MTSRMetsera, Inc. Latest Stock News & Market Updates - StockTitan
Metsera Inc (MTSR): Obesity Drug Biotech Order Book Is "Hot"; Set for Friday IPO Debut - Smartkarma
Metsera Readies $275 Million IPO For Obesity Treatments (Pending:MTSR) - Seeking Alpha
GLP-1RA developer Metsera targets $289m IPO - Pharmaceutical Technology
Three biotechs go public as IPO momentum increases - The Pharma Letter
Obesity drug developer Metsera sets terms for $275M IPO - MSN
Obesity-Focused Metsera Leads Biotech Firms Eyeing IPOs - Law360
Metsera Inc (MTSR): Obesity Drug Company Seeking up to $1.8b IPO Valuation - Smartkarma
Metsera Seeks $289M Raise, $1.78B Valuation in IPO - BioSpace
Weight-loss drug developer Metsera targets up to $1.78 billion valuation in US IPO - MSN
IPO excitement heats up as Metsera targets $1.8B valuation, Aurion joins queue - FirstWord Pharma
Metsera eyes $289M IPO to fund phase 3 weight loss trial - Fierce Biotech
Google Ventures-Backed Biotech Metsera Seeks $292 Million in IPO - Yahoo Finance
Weight-loss drug developer Metsera seeks up to $1.78 billion valuation in US IPO - MSN
Metsera outlines $250M IPO plans as obesity biotech competition rises - Endpoints News
Weight-loss drug developer Metsera reveals wider loss in US IPO filing - MSN
Metsera, Inc. (MTSR): Peeking at the Prospectus for the Next Obesity and Metabolic Diseases Biotech - Smartkarma
2024’s Top 7 VC Raises in Biotech - BioSpace
Metsera Inc (MTSR) 재무 분석
Metsera Inc (MTSR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Metsera Inc 주식 (MTSR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | Director |
Feb 03 '25 |
Buy |
18.00 |
789,998 |
14,219,964 |
8,313,680 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Feb 03 '25 |
Buy |
18.00 |
2,222,222 |
39,999,996 |
18,503,128 |
1.09%
자본화:
|
볼륨(24시간):